Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: Time trends and sociodemographic, comorbidity, and regional correlates

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 1, 2014, Pages 77-86

  Bauer, Mark S ^a,b   Lee, Austin ^a,c,d   Li, Mingfei ^a,e   Bajor, Laura ^a,b   Rasmusson, Ann ^f,g   Kazis, Lewis E ^a,h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d XI'AN UNIVERSITY OF FINANCE AND ECONOMICS   (China)

^e BENTLEY UNIVERSITY   (United States)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antipsychotics; Diffusion of innovations; Pharmacoepidemiology; Post traumatic stress disorder

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AFRICAN AMERICAN; ANXIETY DISORDER; ARTICLE; COMORBIDITY; DEMOGRAPHY; DEPRESSION; FEMALE; HISPANIC; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; POPULATION GROWTH; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SLEEP DISORDER; SUBSTANCE ABUSE; TRAUMATIC BRAIN INJURY; VETERAN;

ANTIPSYCHOTICS; DIFFUSION OF INNOVATIONS; PHARMACOEPIDEMIOLOGY; POST-TRAUMATIC STRESS DISORDER;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OFF-LABEL USE; SOCIOECONOMIC FACTORS; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84891632615     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3507     Document Type: Article

References (68)

1. Kuehn BM. Questionable antipsychotic prescribing remains common, despite serious risks. JAMA 2010; 303(16): 1582-1584.
2. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv 2008; 59(5): 540-546.
3. Hollingworth SA, Siskind DJ, Nissen LM, et al. Patterns of antipsychotic medication use in Australia 2002-2007. Aust N Z J Psychiatry 2010; 44: 372-377.
4. Koskinen H, Martikainen JE, Maljanen T. Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005. Clin Ther 2009; 31: 1469-1477.
5. O'Reilly DJ, Goeree RA, Tarride JE, et al. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06. Can J Clin Pharmacol 2009; 16: e346-e359.
6. Ravindran LN, Stein MB. Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res 2009; 1293: 24-39.
7. Carey B. Drugs found ineffective for veterans' stress. The New York Times, August 2, 2011. http://www.nytimes.com/2011/08/03/health/research/03psych.html?scp=10&sq=august+3%2C+2011&st=nyt [24 August 2011].
8. Brewin B. VA spent $717 million on a drug deemed as effective as a placebo. August 22, 2011. http://www.nextgov.com/nextgov/ng_20110822_6423.php?oref=topstory [24 August 2011].
9. Friedman RA. A call for caution on antipsychotic drugs. The New York Times, August 24, 2012. http://www.nytimes.com/2012/09/25/health/a-call-for-caution-in-the-use-of-antipsychotic-drugs.html?_r=0 [25 September 2012].
10. Villarreal G, Calais LA, Canive JM, et al. Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psycholpharmacol Bull 2007; 40(2): 6-18.
11. Kozaric-Kovacic D, Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features. Int J Neuropsychopharmacol 2007; 10(2): 253-261.
12. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005; 57(5): 474-479.
13. Berger W, Mendlowicz MV, Marques-Portella C, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(2): 169-180.
14. Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008; 23: 1-8.
15. Department of Veterans Affairs (VA). Clinical Practice Guideline for Management of Post-Traumatic Stress Disorder. Department of Veterans Affairs: Washington, DC, 2003.
16. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. American Psychiatric Association: Arlington, VA, 2004.
17. National Collaborating Centre for Mental Health. Posttraumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care. Gaskell and the British Psychological Society: London; Leicester, UK, 2005.
18. Institute of Medicine Committee on Treatment of Posttraumatic Stress Disorder. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. Academy of Science Institute of Medicine, The National Academies Press: Washington, DC, 2008.
19. Foa EB, Keane TM, Friedman MJ, et al. Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies (2nd edn). The Guilford Press: New York, 2008.
20. Benedek DM, Friedman MJ, Zatzick D, et al. Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder. American Psychiatric Publishing, Inc.: Arlington, VA, 2009.
21. Department of Veterans Affairs/Department of Defense (VA/DoD). Clinical Practice Guideline for Management of Post-Traumatic Stress. United States Department of Veterans Affairs/Department of Defense: Washington, DC, 2010.
22. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 2011; 306(5): 493-502.
23. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360(3): 225-235.
24. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(Suppl 1): 20-27.
25. Chwastiak LA, Rosenheck RA, McEvoy JP, et al. The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry 2009; 31: 1-7.
26. US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. Public Health Advisory 2005. US Department of Health and Human Services; April 11, 2005. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm [31 August 2011].
27. Green LW. Public health asks of systems science: to advance our evidence-based practice, can you help us get more practice-based evidence? Am J Public Health 2006; 96(3): 406-409.
28. Horn SD, Gassaway J. Practice-based evidence study design for comparative effectiveness research. Med Care 2007; 45(10 Supl 2): S50-S57.
29. McDonald PW, Viehbeck S. From evidence-based practice making to practice-based evidence making: creating communities of (research) and practice. Health Promot Pract 2007; 8(2): 140-144.
30. Vieweg WV, Julius DA, Fernandez A, et al. Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. Am J Med 2006; 119(5): 383-390.
31. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatr Serv 2009; 60(9): 1175-1181.
32. Hermes ED, Rosenheck R, Desai R, et al. Recent trends in the treatment of posttraumatic stress disorder and other mental disorders in the VHA. Psychiatr Serv 2012; 63: 471-476.
33. Goren JL, Meterko M, Williams S, et al. Antipsychotic prescribing pathways, polypharmacy and clozapine use in schizophrenia. Psychiatr Serv 2013. DOI: 10.1176/appi.ps.002022012.
34. Kazis LE, Miller DR, Skinner KM, et al. Applications of methodologies of the veterans health study in the VA health care system: conclusions and summary. J Ambul Care Manage 2006; 29(2): 182-188.
35. Kazis LE, Nethercot VA, Ren XS, et al. Medication effectiveness studies in the United States Veterans Administration health care system: a model for large integrated delivery systems. Drug Development Res 2006; 67: 217-226.
36. Bangerter A, Gravely A, Cutting A, et al. Brief report: comparison of methods to identify Iraq and Afghanistan war veterans using Department Of Veterans Affairs administrative data. J Rehabil Res Dev 2010; 47(8): 815-821.
37. LaValley MP. Statistical primer for cardiovascular research: logistic regression. Circulation 2008; 117(18): 2395-2399.
38. Hosmer DW, Lemeshow S. Applied Logistic Regression (2nd edn). John Wiley & Sons, Inc: New York, NY, 2000.
39. Bernardy NC, Lund BC, Alexander B, et al. Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry 2012; 73(3): 297-303.
40. Dusetzina SB, Busch AB, Conti RM, et al. Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiol Drug Saf 2012; 21: 1251-1260.
41. Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010; 170(1): 96-103.
42. Lund BC, Abrams TE, Bernardy NC, et al. Benzodiazepine prescribing variation and clinical uncertainty in treating posttraumatic stress disorder. Psychiatr Serv 2013; 64(1): 21-27.
43. Cates ME, Jackson CW, Feldman JM, et al. Metabolic consequences of using low-dose quetiapine for insomnia in psychiatric patients. Community Ment Health. J 2009; 45(4): 251-254.
44. Penfold RB, Kelleher KJ, Wang W, et al. Pediatric uptake of a newly available antipsychotic medication. Pediatrics 2010; 125(3): 475-482.
45. Copeland LA, Zeber JE, Valenstein M, et al. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry 2003; 160(10): 1817-1822.
46. Herbeck DM, West JC, Ruditis I, et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv 2004; 55(6): 677-684.
47. Kreyenbuhl J, Zito JM, Buchanan RW, et al. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull 2003; 29(2): 183-193.
48. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J of Psychiatry 2002; 159(4): 567-572.
49. Mark TL, Dirani R, Slade E, et al. Access to new medications to treat schizophrenia. J Behav Health Services Res 2002; 29(1): 15-29.
50. Opolka JL, Rascati KL, Brown CM, et al. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv. 2004; 55(2): 151-156.
51. Owen RR, Feng W, Thrush CR, et al. Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals. Psychiatr Serv 2001; 52(11): 1523-1525.
52. Valenstein M, McCarthy JF, Ignacio RV, et al. Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatr Serv 2006; 57(1): 70-76.
53. Wang PS, West JC, Tanielian T, et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000; 26(2): 451-457.
54. Yang M, Barner JC, Lawson KA, et al. Antipsychotic medication utilization trends among Texas veterans: 1997-2002. Ann Pharmacother 2008; 42(9): 1229-1238.
55. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspectives. Curr Opin Psychiatry 2011; 24(1): 10-17.
56. Galynker I, Khan A, Grebchenko Y, et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 2005; 66(4): 544.
57. Votruba KL, Rapport LJ, Vangel SJ Jr. Impulsivity and traumatic brain injury: the relations among behavioral observation, performance measures, and rating scales. J Head Trauma Rehabil 2008; 23(2): 65-73.
58. Swick D, Honzel N, Larsen J, et al. Impaired response inhibition in veterans with post-traumatic stress disorder and mild traumatic brain injury. J Int Neuropsychol Soc 2012; 18(5): 917-926.
59. Lertxundi U, Hernandez R, Medrano J, et al. Antipsychotics and seizures: higher risk with atypicals? Seizure 2012; Nov 9. DOI:pii: S1059-1311(12)00284-1. 10.1016/j.seizure.2012.10.009.
60. King M, Essick C. The geography of antidepressant, antipsychotic, and stimulant utilization in the United States. Health Place 2013; 20C: 32-38.
61. Wennberg JE. Time to tackle unwarranted variations in practice. BMJ 2011; 342: d1513.
62. Berger W, Coutinho ES, Figueira I, et al. Rescuers at risk: a systematic review and meta-regression analysis of the worldwide current prevalence and correlates of PTSD in rescue workers. Soc Psychiatr Epidemiol 2012; 47(6): 1001-1011.
63. Hoffman YS, Diamond GM, Lipsitz JD. The challenge of estimating PTSD prevalence in the context of ongoing trauma: the example of Israel during the Second Intifada. J Anxiety Disord 2011; 25(6): 788-793.
64. Dimitry L A systematic review on the mental health of children and adolescents in areas of armed conflict in the Middle East. Child Care Health Dev 2012; 38(2): 153-161.
65. Rogers E Diffusion of Innovations (5th edn), Free Press: New York, 2003.
66. Dearing JW. Evolution of diffusion and dissemination theory. J Public Health Manag Pract 2008;14(2): 99-108.
67. Dearing JW. Applying diffusion of innovation theory to intervention development. Res Soc Work Prac 2009; 19(5): 503-518.
68. Rosenheck RA, Sernyak MJ. Developing a policy for second-generation antipsychotic drugs. Health Aff 2009; 28(5): w782-w793.